Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Alternating Cycles of Carboplatin/Gemcitabine and Carboplatin/Taxol for Advanced Stage NSCLC
This study has been completed.
Sponsored by: University of Saskatchewan
Information provided by: University of Saskatchewan
ClinicalTrials.gov Identifier: NCT00259675
  Purpose

To see the efficacy of using chemotherapies alternatively (carboplatin and gemcitabine alternating with carboplatin and taxol) for pts with stage IIIB (nonresectable and stage IV NSCLC.


Condition Intervention Phase
Non Small Cell Lung Cancer
Drug: carboplatin/gemcitabine, carboplatin/taxol
Phase II

MedlinePlus related topics: Cancer Lung Cancer
Drug Information available for: Carboplatin Gemcitabine hydrochloride Gemcitabine Paclitaxel
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment
Official Title: Treatment of Stages IIIB and IV, Non Small Cell Lung Cancer With Alternating Cycles of Carboplatin/Taxol and Carboplatin/Gemcitabine.

Further study details as provided by University of Saskatchewan:

Primary Outcome Measures:
  • clinical response

Secondary Outcome Measures:
  • progression free survival
  • 1 year survival
  • safety and tolerability of regimen

Estimated Enrollment: 100
Study Start Date: May 2004
Study Completion Date: May 2007
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   19 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically/cytologically documented Non Small Cell Lung Carcinoma.
  2. Stages IIIB and IV disease, not a candidate for definitive treatment with surgery, radiation or radiation plus chemotherapy. (Palliative radiotherapy will be allowed).
  3. Age ≥ 18, < 75 years.
  4. ECOG performance status 2
  5. No serious concomitant psychiatric illness.
  6. Informed consent.
  7. Presence of measurable or evaluable disease on physical examination, CT scan, chest x-ray, ultrasound or MRI scan.

    -

Exclusion Criteria:

1 ) Previous chemotherapy for NSCLC.

2) Known CNS metastases at time of registration.

3) Laboratory values obtained <28 days prior to entry

ANC <1.5 x 109 /L PLT <100 x 109 /L HgB<100 g/L Total bili >1.5 x UNL (upper normal limit) Alk PO4 >3 x UNL AST >3x UNL Cr >1.5 x UNL.

4) Uncontrolled diabetes mellitus, cardiovascular disease, active serious infection or other disease which in the opinion of treating physician, would make this protocol unreasonably hazardous for the patient.

5) Known HIV positive.

6) Palliative radiotherapy to only area of measurable disease.

7) Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, adequately treated non invasive carcinomas, or other cancer from which the patient has been disease free for at least five years.

8) Pregnant or nursing women. Men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, IUD, abstinence, surgical sterilization etc).

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00259675

Locations
Canada, Saskatchewan
Saskatoon cancer ctr
Saskatoon, Saskatchewan, Canada, S7N4H4
Sponsors and Collaborators
University of Saskatchewan
Investigators
Study Chair: Imran Ahmad, MD Saskatchewan Cancer Agency
  More Information

Study ID Numbers: BIO-REB 04-99
Study First Received: November 28, 2005
Last Updated: November 10, 2007
ClinicalTrials.gov Identifier: NCT00259675  
Health Authority: Canada: Ethics Review Committee

Study placed in the following topic categories:
Thoracic Neoplasms
Non-small cell lung cancer
Respiratory Tract Diseases
Paclitaxel
Lung Neoplasms
Lung Diseases
Carboplatin
Gemcitabine
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Carcinoma

Additional relevant MeSH terms:
Antimetabolites
Respiratory Tract Neoplasms
Anti-Infective Agents
Neoplasms by Histologic Type
Antimetabolites, Antineoplastic
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Mitosis Modulators
Physiological Effects of Drugs
Enzyme Inhibitors
Antimitotic Agents
Immunosuppressive Agents
Antiviral Agents
Pharmacologic Actions
Neoplasms
Neoplasms by Site
Radiation-Sensitizing Agents
Therapeutic Uses
Tubulin Modulators
Antineoplastic Agents, Phytogenic

ClinicalTrials.gov processed this record on January 14, 2009